Cargando…

Validation of Pretreatment Prognostic Factors and Prognostic Staging Systems for Small Cell Lung Cancer in a Real-World Data Set

SIMPLE SUMMARY: We present an analysis of a real-world cohort of patients with small cell lung cancer (SCLC) and examine the value of prognostic factors and scores that have been published in recent decades. In our analysis, only a few clinical (age, tumor stage) and a single laboratory parameter (a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagmann, Raphael, Zippelius, Alfred, Rothschild, Sacha I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179878/ https://www.ncbi.nlm.nih.gov/pubmed/35681605 http://dx.doi.org/10.3390/cancers14112625

Ejemplares similares

Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience
por: Hagmann, Raphael, et al.
Publicado: (2015)

Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort
por: Conen, Katrin, et al.
Publicado: (2016)

Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients – evaluation of outcome and prognostic factors: A retrospective multicenter study
por: Fuchs, Julia, et al.
Publicado: (2021)

Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib
por: Liu, Jingjing, et al.
Publicado: (2020)

Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis
por: Xie, Yulian, et al.
Publicado: (2023)

Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients
por: Huang, Li‐Ling, et al.
Publicado: (2021)

Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes
por: Moser, Sarah Sharman, et al.
Publicado: (2021)

Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients
por: Ma, Xiangjuan, et al.
Publicado: (2021)

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
por: Mu, Yuxin, et al.
Publicado: (2019)

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer
por: Sun, Bochen, et al.
Publicado: (2022)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2017)

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
por: Britschgi, Christian, et al.
Publicado: (2020)

Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma
por: Wang, Bo, et al.
Publicado: (2015)

Prognostic Factor and Clinical Outcome in Stage III Non–Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population
por: Kim, Ho Cheol, et al.
Publicado: (2021)

Prognostic value of pretreatment smoking status for small cell lung cancer: A meta‐analysis
por: Huang, Liling, et al.
Publicado: (2020)

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
por: Sauta, Elisabetta, et al.
Publicado: (2023)

Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2019)

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
por: Rothschild, Sacha I.
Publicado: (2015)

P15 VALIDATION OF THE NOVEL EUROPEAN MYELOMA NETWORK PROGNOSTIC SCORE (R2-ISS) IN AN INDEPENDENT REAL-WORLD SETTING
por: Cengiz Seval, G, et al.
Publicado: (2023)

PB2027: PROGNOSTICATION IN THE EVERYDAY MYELOMA CLINIC. A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS VALIDATED IN REAL WORLD POPULATIONS
por: Redder, L., et al.
Publicado: (2022)

Prognostic Value of Pretreatment D-Dimer Level in Small-Cell Lung Cancer: A Meta-Analysis
por: Li, Jialong, et al.
Publicado: (2021)

Construction and validation of a survival prognostic model for stage III hepatocellular carcinoma: a real-world, multicenter clinical study
por: Hao, Shuai, et al.
Publicado: (2023)

Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study
por: Wallrabenstein, Till, et al.
Publicado: (2023)

Real-World Effectiveness and Prognostic Factors Analysis of Stages I–III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy
por: Liu, Zuo, et al.
Publicado: (2021)

Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
por: Longo, Vito, et al.
Publicado: (2022)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
por: Rothschild, Sacha I
Publicado: (2016)

Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases
por: Yu, Xiaoqing, et al.
Publicado: (2019)

STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data
por: Wang, Zhenxin, et al.
Publicado: (2020)

Pretreatment Hemoglobin Level Is an Independent Prognostic Factor in Patients with Lung Adenocarcinoma
por: Zhang, Yue-Hua, et al.
Publicado: (2018)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild, Sacha I
Publicado: (2014)

The prognostic value of pretreatment prognostic nutritional index in patients with small cell lung cancer and it’s influencing factors: a meta-analysis of observational studies
por: Jiang, Ai-Min, et al.
Publicado: (2020)

The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis
por: Lu, Yan, et al.
Publicado: (2020)

Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients
por: Zeng, Qingpeng, et al.
Publicado: (2021)

Treatment, Outcome and Prognostic Factors in Renal Cell Carcinoma - A Single Center Study (2000-2010)
por: Achermann, Christof, et al.
Publicado: (2016)

Prognostic value of pretreatment inflammatory biomarkers in primary small cell carcinoma of the esophagus
por: Wang, Nan, et al.
Publicado: (2019)

Prognostic value of pretreatment systemic inflammatory markers in patients with stage I endometrial cancer
por: Ahn, Jung Hwan, et al.
Publicado: (2022)

Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer
por: Zhang, Yi, et al.
Publicado: (2020)

Prognostic factors for treatment response and survival outcomes after first-line management of Stage 4 non-small cell lung cancer: A real-world Indian perspective
por: Garg, Avneet, et al.
Publicado: (2022)

The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer
por: Kasajima, Masashi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mq8fto459fmfjbvfdr62id0lv0